Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00649025 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
A Phase 3 study, sponsored by SkyePharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 438
- Enrollment target
NCT00649025: Completed Phase 3 study, sponsored by SkyePharma.
NCT00649025 is a Phase 3 study that has completed, run by SkyePharma. The registered enrollment target is 438 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00649025, a Phase 3 study, has completed, sponsored by SkyePharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 438 participants
- Enrollment target
Study Summary
The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of two medications in one inhaler. The purpose of this study is to determine how well your asthma is controlled when taking one of the three treatment.
Interventions
- DRUG FlutiForm 250/10
- DRUG SKP-Fluticasone
- DRUG Flovent Fluticasone HFA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00649025
The ClinicalTrials.gov registry entry for NCT00649025 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 438 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SkyePharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FlutiForm 250/10 is the first listed.
NCT00649025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00649025 about?
NCT00649025 is a clinical study titled "A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults". The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of two medications in one inhaler. The purpose of this study is to determine how well your asthma is controlled when taking one of the thr...
What is the current status of trial NCT00649025?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 438 participants. The study started on 2008-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00649025?
The interventions under investigation include: FlutiForm 250/10 (DRUG), SKP-Fluticasone (DRUG), Flovent Fluticasone HFA (DRUG).
Who is sponsoring clinical trial NCT00649025?
This trial is sponsored by SkyePharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.